WHO Pharmaceuticals Newsletter 2002, No. 02
(2002; 18 pages) View the PDF document
Table of Contents
View the documentEDITORIAL
Open this folder and view contentsREGULATORY MATTERS
Close this folderSAFETY OF MEDICINES
View the documentALENDRONATE - Case reports of pancreastitis with alendronic acid suggest a link? (Canada)
View the documentAMIODARONE - Reports of pulmonary toxicity (Australia)
View the documentANTIRETROVIRAL THERAPY (ART) - Lipodystrophy syndrome with ART under-reported in Canada (Canada)
View the documentARISTOLOCHIA - Safety update from Oman (Sultanate of Oman)
View the documentBUPROPION - Risk of seizure (UK)
View the documentCLOZAPINE - Clear association with myocarditis; revised labelling to indicate cardiovascular toxicity (Canada)
View the documentDROPERIDOL - Warnings of cardiovascular toxicity (Canada)
View the documentEPHEDRINE/EPHEDRA - Products recalled following risk assessment (Canada)
View the documentMETHOTREXATE - Adverse reactions influence treatment and prescribing decisions (India)
View the documentOLANZAPINE - Cardiomyopathy: case report (Sweden)
View the documentROFECOXIB/WARFARIN - Clinically significant interactions possible (Australia)
View the documentROSIGLITAZONE - Reminder about restrictions in use (Singapore)
View the documentSIBUTRAMINE - Safety reviews on anti-obesity drug (Canada, Europe)
View the documentSODIUM PICOSULFATE - Reports of severe electrolyte disturbances (Australia)
View the documentSTATINS - News from India and Singapore (India)
View the documentSTAVUDINE - Safety information updated (Canada, USA)
View the documentZOLPIDEM - Neurological and psychiatric reactions reported (Australia)
Open this folder and view contentsDRUG OF CURRENT INTEREST
View the documentADVERSE DRUG REACTIONS (ADR) - ASSOCIATIONS
Open this folder and view contentsFEATURE
View the documentEVENTS & ANNOUNCEMENTS
 

ARISTOLOCHIA - Safety update from Oman (Sultanate of Oman)

Sultanate of Oman. The Directorate General of Pharmaceutical Affairs & Drug Control (DGPA&DC) in the Sultanate of Oman has made a decision to prohibit the import and marketing of any herbal product or traditional medicines containing aristolochic acid. The decision was made in light of information received by the directorate that aristolochic acid consumption has been associated with severe kidney toxicity and also the development of cancer of the urinary tract.

Reference:

Directorate General of Pharmaceutical Affairs & Drug Control Pharmaceutical Newsletter 9: 1, No. 3, 2001.

to previous section to next section
 

Last updated: May 3, 2013